New eye drops aim to halt blinding disease in seniors
NCT ID NCT06659549
First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 4 times
Summary
This study tests whether GAL-101 eye drops can slow the growth of geographic atrophy, a form of advanced age-related macular degeneration that causes blind spots. About 110 adults aged 55 and older with early-stage atrophy will use the drops or a placebo daily for up to two years. The goal is to see if the treatment can keep the damage from reaching the center of vision.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GAL-101 eye drops
- What this could lead to
- If successful, this could slow vision loss from geographic atrophy and help preserve central vision in elderly patients.
- What could go wrong
- This is an early Phase 2 trial with only 110 participants. The drug may not slow atrophy growth, and daily eye drops may be inconvenient or cause irritation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY OF THE MACULA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Akhali Mzera Limited
RECRUITINGTbilisi, 0162, Georgia
-
Bay Area Retina Associates
RECRUITINGWalnut Creek, California, 94598, United States
-
Caucasus Medical Centre LLC
RECRUITINGTbilisi, 0186, Georgia
-
Centre Monticelli Paradis d'Ophtalmologie
RECRUITINGMarseille, 13008, France
-
Centre Ophtalmologique Odéon
NOT_YET_RECRUITINGParis, 75006, France
-
Centre Rétine Gallien
RECRUITINGBordeaux, 33000, France
-
Centre médico-chirurgical de Touraine
RECRUITINGTours, 37540, France
-
Chichua Medical Centre Mzera LLC
WITHDRAWNTbilisi, Georgia
-
Cumberland Valley Retina Consultants
SUSPENDEDHagerstown, Maryland, 21740, United States
-
Dietrich Bonhoeffer Klinikum
RECRUITINGNeubrandenburg, 17036, Germany
-
Hadassah Medical Center
RECRUITINGJerusalem, 9112001, Israel
-
Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon
RECRUITINGLyon, 69317, France
-
Institute of Eye Surgery (IOES Waterford)
RECRUITINGWaterford, X91 DH9W, Ireland
-
Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe
RECRUITINGMilan, Milano, 20123, Italy
-
Medizinische Hochschule Hannover Augenklinik
NOT_YET_RECRUITINGHanover, 30625, Germany
-
Ophthalmological Center After S.V. Malayan
RECRUITINGYerevan, 0048, Armenia
-
Retina-Vitreous Associates Medical Group
RECRUITINGBeverly Hills, California, 90211, United States
-
Tel Aviv Medical Center
RECRUITINGTel Aviv, 6423906, Israel
-
UNIVERSITÄTSKLINIKUM ULM Klinik für Augenheilkunde
NOT_YET_RECRUITINGUlm, 89075, Germany
-
UOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in OftalmologiaUOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia
RECRUITINGRoma, Roma, 00184, Italy
-
UPMC Kildare Hospital Prosperous Rd Clane, Kildare Ireland
NOT_YET_RECRUITINGKildare, W91 W535, Ireland
-
Unità di Oculistica, IRCCS Ospedale San Raffaele
RECRUITINGMilan, Milano, 20132, Italy
-
Universitäts-Augenklinik Bonn
RECRUITINGBonn, 53127, Germany
-
Universitätsklinikum Freiburg Klinik für Augenheilkunde
RECRUITINGFreiburg im Breisgau, 79106, Germany
-
Universitätsklinikum Tübingen, Department für Augenheilkunde.
NOT_YET_RECRUITINGTübingen, 72076, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.